| P50 | author | Stephen B Soumerai | Q92319331 |
| P2093 | author name string | Christine Y Lu | |
| | Gregory Simon | |
| P2860 | cites work | Persisting decline in depression treatment after FDA warnings | Q37504480 |
| | False Dichotomies and Health Policy Research Designs: Randomized Trials Are Not Always the Answer. | Q37605231 |
| | Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness. | Q37643407 |
| | The Effects of the Transition From Medicaid to Medicare on Health Care Use for Adults With Mental Illness | Q39710117 |
| | Trends in US emergency department visits for suicide attempts, 1992-2001. | Q39855132 |
| | Changes in US antidepressant and antipsychotic prescription patterns during a period of FDA actions | Q43202386 |
| | Unintended consequences of a Medicaid prescription copayment policy | Q45787430 |
| | National study of US emergency department visits for attempted suicide and self-inflicted injury, 1997-2001. | Q46720224 |
| | Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs | Q46911904 |
| | Conflict of Interest and Legal Issues for Investigators and Authors | Q47562765 |
| | Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia | Q50117907 |
| | Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity | Q50147877 |
| | Medicare Part D is associated with reducing the financial burden of health care services in Medicare beneficiaries with diagnosed diabetes. | Q51223163 |
| | Near Real-time Surveillance for Consequences of Health Policies Using Sequential Analysis. | Q53414337 |
| | Effect of government and commercial warnings on reducing prescription misuse: the case of propoxyphene. | Q64897831 |
| | Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes | Q67971707 |
| | Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs | Q80412509 |
| | Effect of regulatory warnings on antidepressant prescribing for children and adolescents | Q80558017 |
| | How Do You Know Which Health Care Effectiveness Research You Can Trust? A Guide to Study Design for the Perplexed | Q24273264 |
| | How complete are E-codes in commercial plan claims databases? | Q28390387 |
| | Antidepressants and suicide risk: how did specific information in FDA safety warnings affect treatment patterns? | Q33568855 |
| | News coverage of FDA warnings on pediatric antidepressant use and suicidality | Q33584737 |
| | Evidence of self-report bias in assessing adherence to guidelines | Q33704445 |
| | Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study | Q33774659 |
| | Generic penetration in the retail antidepressant market | Q33969166 |
| | Changes in use of lipid-lowering medications among black and white dual enrollees with diabetes transitioning from Medicaid to Medicare Part D drug coverage | Q34055633 |
| | Characterizing Declines in Pediatric Antidepressant Use After New Risk Disclosures | Q34283311 |
| | Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents | Q34582162 |
| | Effects of Professional and Media Warnings about the Association between Aspirin Use in Children and Reye's Syndrome | Q35228352 |
| | History Bias, Study Design, and the Unfulfilled Promise of Pay-for-Performance Policies in Health Care | Q37052695 |
| | A critical review of methods to evaluate the impact of FDA regulatory actions. | Q37301216 |
| | Asthma Treatments and Mental Health Visits After a Food and Drug Administration Label Change for Leukotriene Inhibitors | Q37402764 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 384-390 | |
| P577 | publication date | 2018-05-01 | |
| P1433 | published in | Medical Care | Q15762119 |
| P1476 | title | Counter-Point: Staying Honest When Policy Changes Backfire | |
| P478 | volume | 56 | |